arrow
B

Bruno Daniele

university of bologna
H指数:50
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA)

胆管癌的分子谱分析和匹配的靶向治疗: 来自意大利数据集 (ANITA) 的结果

2025-12-270
OAAI
Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma

Radiopsy:一项关于定量多参数全身磁共振成像以区分冒烟型骨髓瘤和多发myeloma的前瞻性观察研究

2025-12-011
OAAI
Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Società Italiana di Reumatologia (SIR), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Gastroenterologia (SIGE), Società Italiana di Malattie Infettive e Tropicali (SIMIT)

乙型肝炎病毒感染的管理:意大利肝病研究协会(AISF)、意大利医学肿瘤学会(AIOM)、意大利骨髓移植小组(GITMO)、意大利风湿病学会(SIR)、意大利器官移植学会(SITO)、意大利胃肠病学学会(SIGE)、意大利感染病与热带病学会(SIMIT)立场文件

2025-11-100
PRE
Cancer Prevention at Work (CPW) project: Rationale, framework and research protocol

工作中的癌症预防 (CPW) 项目: 基本原理,框架和研究方案

2025-11-031
PRE
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
2025-02-010
PRE
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma

索拉非尼作为阿特珠单抗-贝伐单抗治疗不可切除肝细胞癌的二线治疗的次优结果

2024-12-012
OAAI
Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion-positive glioblastoma
2024-11-200
OAAI
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
2024-05-019
PRE
The synergic effect of metformin with atezolizumab/ bevacizumab in masld hcc patients: a retrospective study from arte multicentric Italian dataset
2024-02-010
PRE
Clinical impact of relative dose intensity of cabozantinib during the first 8 weeks and of subsequent dose reductions in patients with unresectable hepatocellular carcinoma
2023-09-010
PRE
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data
2023-07-1450
OAAI
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study
2023-07-0112
PRE